US OptionsDetailed Quotes
ARQT250516P17500
- 4.10
- +0.70+20.59%
15min DelayClose May 7 16:00 ET
4.20High4.10Low
4.20Open3.40Pre Close10 Volume25 Open Interest17.50Strike Price4.15KTurnover162.02%IV2.19%PremiumMay 16, 2025Expiry Date3.80Intrinsic Value100Multiplier8DDays to Expiry0.30Extrinsic Value100Contract SizeAmericanOptions Type-0.8100Delta0.0815Gamma3.34Leverage Ratio-0.0532Theta-0.0030Rho-2.71Eff Leverage0.0056Vega
Arcutis Biotherapeutics Stock Discussion
Arcutis Biotherapeutics
(ARQT.US)
Tonix Pharmaceuticals
(TNXP.US)
As of March 25, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price act...
Could This New Eczema Cream Bring Relief to Millions of Toddlers? FDA Now Reviewing
📊⚡️📊
Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million
Positive
▪️Q4 2024 revenue grew 366% YoY to $63 million
▪️Full-year 2024 revenue increased 449% YoY to $160 million
▪️Strong quarter-over-quarter growth of 41% in Q4 2024
▪️Robust liquidity position of $329 million including available debt
▪️Option to re-draw $100 million deb...
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you don’t a...
Arcutis Biotherapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Rubric Capital Management LP(9.38%),David Rosen(9.38%)
Long-term! 😜
1 MINUTE AGO, 8:20 AM EDT
VIA GLOBENEWSWIRE
No comment yet